Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$1.8 million.

  • Autolus Therapeutics' Cash from Financing Activities fell 105891.89% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.5 million, marking a year-over-year decrease of 9509.18%. This contributed to the annual value of $589.6 million for FY2024, which is 6686715.74% up from last year.
  • Per Autolus Therapeutics' latest filing, its Cash from Financing Activities stood at -$1.8 million for Q3 2025, which was down 105891.89% from -$768000.0 recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Cash from Financing Activities high stood at $561.4 million for Q1 2024, and its period low was -$2.1 million during Q2 2024.
  • For the 5-year period, Autolus Therapeutics' Cash from Financing Activities averaged around $64.3 million, with its median value being $23000.0 (2023).
  • As far as peak fluctuations go, Autolus Therapeutics' Cash from Financing Activities plummeted by 6900000.0% in 2023, and later skyrocketed by 13036521.74% in 2024.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Cash from Financing Activities stood at $147.4 million in 2021, then skyrocketed by 51.62% to $223.5 million in 2022, then crashed by 99.99% to $23000.0 in 2023, then skyrocketed by 130365.22% to $30.0 million in 2024, then plummeted by 105.91% to -$1.8 million in 2025.
  • Its Cash from Financing Activities was -$1.8 million in Q3 2025, compared to -$768000.0 in Q2 2025 and $30.0 million in Q4 2024.